Results 11 to 20 of about 1,881,665 (353)

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Science, 2020
Interferons interfere with lung repair Interferons (IFNs) are central to antiviral immunity. Viral recognition elicits IFN production, which in turn triggers the transcription of IFN-stimulated genes (ISGs), which engage in various antiviral functions ...
J. Hadjadj, N. Yatim, L. Barnabei, A. Corneau, J. Boussier, Nikaïa Smith, H. Péré, B. Charbit, V. Bondet, C. Chenevier-Gobeaux, P. Breillat, Nicolas Carlier, R. Gauzit, C. Morbieu, F. Pène, N. Marin, N. Roche, T. Szwebel, S. Merkling, J. Treluyer, D. Veyer, L. Mouthon, C. Blanc, P. Tharaux, F. Rozenberg, A. Fischer, D. Duffy, F. Rieux-Laucat, S. Kernéis, B. Terrier   +29 more
semanticscholar   +1 more source

Type I interferon and cancer

Immunological Reviews, 2023
Type I interferon (IFN) is a class of proinflammatory cytokines with a dual role on malignant transformation, tumor progression, and response to therapy.
P. Holicek, Emma Guilbaud, V. Klapp, I. Truxova, R. Spisek, L. Galluzzi, J. Fucikova   +6 more
semanticscholar   +1 more source

ADAR1 averts fatal type I interferon induction by ZBP1

Nature, 2022
Mutations of the ADAR1 gene encoding an RNA deaminase cause severe diseases associated with chronic activation of type I interferon (IFN) responses, including Aicardi–Goutières syndrome and bilateral striatal necrosis1–3.
Huipeng Jiao, Laurens Wachsmuth, Simone Wolf, Juliane Lohmann, M. Nagata, G. G. Kaya, N. Oikonomou, V. Kondylis, M. Rogg, M. Diebold, Simon E. Tröder, B. Zevnik, M. Prinz, C. Schell, G. Young, G. Kassiotis, M. Pasparakis   +16 more
semanticscholar   +1 more source

Type I interferon-mediated tumor immunity and its role in immunotherapy

Cellular and Molecular Life Sciences, 2022
Immune checkpoint blockade (ICB) therapies have achieved remarkable clinical responses in patients with many different types of cancer; however, most patients who receive ICB monotherapy fail to achieve long-term responses, and some tumors become ...
Renren Yu, B. Zhu, Degao Chen
semanticscholar   +1 more source

Activation and evasion of type I interferon responses by SARS-CoV-2

Nature Communications, 2020
The pandemic of COVID-19 has posed an unprecedented threat to global public health. However, the interplay between the viral pathogen of COVID-19, SARS-CoV-2, and host innate immunity is poorly understood.
X. Lei, Xiaojing Dong, Ruiyi Ma, Wenjing Wang, Xia Xiao, Zhongqin Tian, Conghui Wang, Ying Wang, Li Li, L. Ren, Fei Guo, Zhendong Zhao, Zhuo Zhou, Zichun Xiang, Jianwei Wang   +14 more
semanticscholar   +1 more source

Insights Into Type I and III Interferons in Asthma and Exacerbations

Frontiers in Immunology, 2020
Asthma is a highly prevalent, chronic respiratory disease that impacts millions of people worldwide and causes thousands of deaths every year.
Helen E. Rich, Danielle Antos, Natalie R. Melton, John F. Alcorn, Michelle L. Manni   +4 more
doaj   +1 more source

The Role of Interferons in the Pathogenesis of Sjögren’s Syndrome and Future Therapeutic Perspectives

Biomolecules, 2021
There is a great deal of evidence pointing to interferons (IFNs) as being key cytokines in the pathogenesis of different systemic autoimmune diseases, including primary Sjögren’s syndrome (pSS).
Nicoletta Del Papa, Antonina Minniti, Maurizio Lorini, Vincenzo Carbonelli, Wanda Maglione, Francesca Pignataro, Nicola Montano, Roberto Caporali, Claudio Vitali   +8 more
doaj   +1 more source

Type I interferon: potential therapeutic target for psoriasis? [PDF]

PLoS ONE, 2008
BACKGROUND: Psoriasis is an immune-mediated disease characterized by aberrant epidermal differentiation, surface scale formation, and marked cutaneous inflammation.
Yihong Yao, Laura Richman, Chris Morehouse, Melissa de los Reyes, Brandon W Higgs, Anmarie Boutrin, Barbara White, Anthony Coyle, James Krueger, Peter A Kiener, Bahija Jallal   +10 more
doaj   +1 more source

Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19

Science Translational Medicine, 2021
Description Type I interferon autoantibodies in patients with COVID-19 are associated with poor interferon responses and increased LAIR1 abundance in leukocytes.
M. V. D. van der Wijst, S. Vazquez, G. Hartoularos, P. Bastard, T. Grant, R. Bueno, David S. Lee, J. Greenland, Yang Sun, Richard K. Perez, A. Ogorodnikov, A. Ward, S. Mann, K. Lynch, C. Yun, D. Havlir, G. Chamie, C. Marquez, B. Greenhouse, M. Lionakis, P. Norris, L. Dumont, K. Kelly, Peng Zhang, Qian Zhang, A. Gervais, Tom Le Voyer, Alexander Whatley, Yichen Si, A. Byrne, A. Combes, A. Rao, Yun S. Song, G. Fragiadakis, K. Kangelaris, C. Calfee, D. Erle, C. Hendrickson, M. Krummel, P. Woodruff, C. Langelier, J. Casanova, J. Derisi, Mark S. Anderson, Chun Jimmie Ye   +44 more
semanticscholar   +1 more source

Plasmacytoid Dendritic Cells Mediate Myocardial Ischemia/Reperfusion Injury by Secreting Type I Interferons

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background We previously demonstrated that ischemically injured cardiomyocytes release cell‐free DNA and HMGB1 (high mobility group box 1 protein) into circulation during reperfusion, activating proinflammatory responses and ultimately exacerbating ...
Lina Lai, Aimee Zhang, Boris Yang, Eric J. Charles, Irving L. Kron, Zequan Yang   +5 more
doaj   +1 more source